Background. Lung cancer is one of the leading diagnosed cancers worldwide, and microRNAs could be used as biomarkers to diagnose lung cancer. hsa-miR-195 has been demonstrated to affect the prognosis of NSCLC (non-small-cell lung cancer) in a previous study. However, the diagnostic value of hsa-miR-195-5p in lung cancer has not been investigated. Methods. To evaluate the ability of hsa-miR-195-5p to diagnose lung cancer, we compared the expression of hsa-miR-195-5p in lung cancer patients, COPD patients, and normal controls. Receiver operating characteristic (ROC) curve analysis was performed to investigate the sensitivity and specificity of hsa-miR-195-5p. Coexpression network and pathway analysis were carried out to explore the mechanism. Results. We found that hsa-miR-195-5p had lower expression in lung cancer and COPD patients than in normal controls, and the AUC was 0.92 for diagnosing lung cancer. hsa-miR-143 correlated with hsa-miR-195-5p, and by combining these two microRNAs, the AUC was 0.97 for diagnosing lung cancer. Conclusions. hsa-miR-195-5p may act as a biomarker that contributes to the diagnosis of lung cancer and the detection of its high-risk population.

中文翻译：

---

用于检测肺癌风险的 MicroRNA 生物标志物 hsa-miR-195-5p。

背景。肺癌是世界范围内诊断出的主要癌症之一，microRNA可作为诊断肺癌的生物标志物。在之前的研究中， hsa-miR-195已被证明会影响 NSCLC（非小细胞肺癌）的预后。然而，尚未研究hsa-miR-195-5p在肺癌中的诊断价值。方法。为了评估hsa-miR-195-5p诊断肺癌的能力，我们比较了hsa-miR-195-5p在肺癌患者、COPD 患者和正常对照中的表达。进行接受者操作特征（ROC）曲线分析以研究hsa-miR-195-5p的敏感性和特异性. 进行共表达网络和通路分析以探索其机制。结果。我们发现hsa-miR-195-5p在肺癌和COPD患者中的表达低于正常对照组，诊断肺癌的AUC为0.92。hsa-miR-143与hsa-miR-195-5p相关，通过结合这两种 microRNA，诊断肺癌的 AUC 为 0.97。结论。hsa-miR-195-5p可能作为一种生物标志物，有助于肺癌的诊断和高危人群的检测。